Altered MicroRNA expression after infection with human cytomegalovirus leads to TIMP3 downregulation and increased shedding of metalloprotease substrates, including MICA

Journal of Immunology

Volumn 193, Issue 3, 2014, Pages 1344-1352

  Esteso, Gloria ^a   Luzón, Elisa ^a   Sarmiento, Elisabeth ^b   Gómez Caro, Ruth ^a   Steinle, Alexander ^c   Murphy, Gillian ^d   Carbone, Javier ^b   Valés Gómez, Mar ^a   Reyburn, Hugh T ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE 14; MEMBRANE PROTEIN; MICRORNA; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN MICA; PROTEIN MICB; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOWN REGULATION; GENE EXPRESSION; IMMUNOMODULATION; MRNA EXPRESSION ASSAY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL LINE, TUMOR; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MATRIX METALLOPROTEINASE 14; MICRORNAS; PRIMARY CELL CULTURE; SUBSTRATE SPECIFICITY; TISSUE INHIBITOR OF METALLOPROTEINASE-3; UP-REGULATION;

EID: 84906092044     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303441     Document Type: Article

References (59)

1. Murphy, G., A. Murthy, and R. Khokha. 2008. Clipping, shedding and RIPping keep immunity on cue. Trends Immunol. 29: 75-82.
2. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
3. Nausch, N., and A. Cerwenka. 2008. NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
4. Doubrovina, E. S., M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O'Reilly, B. Dupont, and Y. M. Vyas. 2003. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171: 6891-6899.
5. Wu, J. D., L.M.Higgins, A. Steinle, D. Cosman, K. Haugk, and S. R. Plymate. 2004. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114: 560-568.
6. Salih, H. R., S. Holdenrieder, and A. Steinle. 2008. Soluble NKG2D ligands: prevalence, release, and functional impact. Front. Biosci. 13: 3448-3456.
7. Cerboni, C., F. Neri, N. Casartelli, A. Zingoni, D. Cosman, P. Rossi, A. Santoni, and M. Doria. 2007. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J. Gen. Virol. 88: 242-250.
8. Ward, J., M. Bonaparte, J. Sacks, J. Guterman, M. Fogli, D. Mavilio, and E. Barker. 2007. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood 110: 1207-1214.
9. Wen, C., X. He, H. Ma, N. Hou, C. Wei, T. Song, Y. Zhang, L. Sun, Q. Ma, and H. Zhong. 2008. Hepatitis C virus infection downregulates the ligands of the activating receptor NKG2D. Cell. Mol. Immunol. 5: 475-478.
10. Sène, D., F. Levasseur, M. Abel, M. Lambert, X. Camous, C. Hernandez, V. Pène, A. R. Rosenberg, E. Jouvin-Marche, P. N. Marche, et al. 2010. Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5Amediated imbalance of inflammatory cytokines. PLoS Pathog. 6: e1001184.
11. Campbell, J. A., D. S. Trossman, W. M. Yokoyama, and L. N. Carayannopoulos. 2007. Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D. J. Exp. Med. 204: 1311-1317.
12. Cosman, D., J. Müllberg, C. L. Sutherland, W. Chin, R. Armitage, W. Fanslow, M. Kubin, and N. J. Chalupny. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123-133.
13. Valés-Gómez, M., H. Browne, and H. T. Reyburn. 2003. Expression of the UL16 glycoprotein of Human Cytomegalovirus protects the virus-infected cell from attack by natural killer cells. BMC Immunol. 4: 4.
14. Nolting, A., A. S. Dugast, S. Rihn, R. Luteijn, M. F. Carrington, K. Kane, S. Jost, I. Toth, E. Nagami, G. Faetkenheuer, et al. 2010. MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction. Virology 406: 12-20.
15. Matusali, G., H. K. Tchidjou, G. Pontrelli, S. Bernardi, G. D'Ettorre, V. Vullo, A. R. Buonomini, M. Andreoni, A. Santoni, C. Cerboni, and M. Doria. 2013. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. FASEB J. 27: 2440-2450.
16. Humbert, M., P. Roux-Lombard, J. Cerrina, A. Magnan, G. Simonneau, P. Dartevelle, P. Galanaud, J. M. Dayer, and D. Emilie. 1994. Soluble TNF receptors (TNF-sR55 and TNF-sR75) in lung allograft recipients displaying cytomegalovirus pneumonitis. Am. J. Respir. Crit. Care Med. 149: 1681-1685.
17. Jakobsen, P. H., K. K. Dodt, C. N. Meyer, T. Katzenstein, J. Gerstoft, and P. Skinhøj. 1998. Increased levels of soluble tumour necrosis factor receptor-I (P55) and decreased IgG1 reactivities in HIV-1 patients with cytomegalovirus disease. Scand. J. Immunol. 47: 591-595.
18. Nordøy, I., F. Müller, K. P. Nordal, H. Rollag, P. Aukrust, and S. S. Frøland. 2000. Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection. Clin. Exp. Immunol. 120: 333-337.
19. Eriksson, B. M., J. Sjölin, K. Claesson, B. Z. Wirgart, L. Grillner, and T. H. Tötterman. 2001. Circulating soluble vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in immunocompetent and renal transplant patients: correlation with cytomegalovirus disease and renal function. Scand. J. Infect. Dis. 33: 350-354.
20. Valés-Gómez, M., A. Winterhalter, P. Roda-Navarro, A. Zimmermann, L. Boyle, H. Hengel, A. Brooks, and H. T. Reyburn. 2006. The human cytomegalovirus glycoprotein UL16 traffics through the plasma membrane and the nuclear envelope. Cell. Microbiol. 8: 581-590.
21. Rothlein, R., E. A. Mainolfi, M. Czajkowski, and S. D. Marlin. 1991. A form of circulating ICAM-1 in human serum. J. Immunol. 147: 3788-3793.
22. Rothlein, R., M. L. Dustin, S. D. Marlin, and T. A. Springer. 1986. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J. Immunol. 137: 1270-1274.
23. Murphy, G., and F. Willenbrock. 1995. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 248: 496-510.
24. Lee, M. H., V. Knäuper, J. D. Becherer, and G. Murphy. 2001. Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. Biochem. Biophys. Res. Commun. 280: 945-950.
25. Agüera-González, S., C. C. Gross, L. Fernández- Messina, O. Ashiru, G. Esteso, H. C. Hang, H. T. Reyburn, E. O. Long, and M. Valés-Gómez. 2011. Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding. Eur. J. Immunol. 41: 3667-3676.
26. McSharry, B. P., C. J. Jones, J. W. Skinner, D. Kipling, and G. W. Wilkinson. 2001. Human telomerase reverse transcriptase-immortalized MRC-5 and HCA2 human fibroblasts are fully permissive for human cytomegalovirus. J. Gen. Virol. 82: 855-863.
27. Moffat, J., D. A. Grueneberg, X. Yang, S. Y. Kim, A. M. Kloepfer, G. Hinkle, B. Piqani, T. M. Eisenhaure, B. Luo, J. K. Grenier, et al. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124: 1283-1298.
28. Friesland, M., L. Mingorance, J. Chung, F. V. Chisari, and P. Gastaminza. 2013. Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. J. Virol. 87: 6377-6390.
29. Wang, B., S. H. Hsu, S. Majumder, H. Kutay, W. Huang, S. T. Jacob, and K. Ghoshal. 2010. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 29: 1787-1797.
30. Zou, Y., W. Bresnahan, R. T. Taylor, and P. Stastny. 2005. Effect of human cytomegalovirus on expression of MHC class I-related chains A. J. Immunol. 174: 3098-3104.
31. Wilkinson, G. W., P. Tomasec, R. J. Stanton, M. Armstrong, V. Prod'homme, R. Aicheler, B. P. McSharry, C. R. Rickards, D. Cochrane, S. Llewellyn-Lacey, et al. 2008. Modulation of natural killer cells by human cytomegalovirus. J. Clin. Virol. 41: 206-212.
32. Waldhauer, I., D. Goehlsdorf, F. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H. G. Rammensee, and A. Steinle. 2008. Tumorassociated MICA is shed by ADAM proteases. Cancer Res. 68: 6368-6376.
33. Boutet, P., S. Agüera-González, S. Atkinson, C. J. Pennington, D. R. Edwards, G. Murphy, H. T. Reyburn, and M. Valés- Gómez. 2009. Cutting edge: the metalloproteinase ADAM17/TNF-alpha- converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J. Immunol. 182: 49-53.
34. Kohga, K., T. Takehara, T. Tatsumi, H. Ishida, T. Miyagi, A. Hosui, and N. Hayashi. 2010. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by downregulating a disintegrin and metalloproteinase 9. Hepatology 51: 1264-1273.
35. Liu, G., C. L. Atteridge, X. Wang, A. D. Lundgren, and J. D. Wu. 2010. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J. Immunol. 184: 3346-3350.
36. Baker, A. H., D. R. Edwards, and G. Murphy. 2002. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115: 3719-3727.
37. Amour, A., C. G. Knight, W. R. English, A. Webster, P. M. Slocombe, V. Knäuper, A. J. Docherty, J. D. Becherer, C. P. Blobel, and G. Murphy. 2002. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. 524: 154-158.
38. Borroto, A., S. Ruiz-Paz, T. V. de la Torre, M. Borrell-Pages, A. Merlos-Suarez, A. Pandiella, C. P. Blobel, J. Baselga, and J. Arribas. 2003. Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. J. Biol. Chem. 278: 25933-25939.
39. Kaiser, B. K., D. Yim, I. T. Chow, S. Gonzalez, Z. Dai, H. H. Mann, R. K. Strong, V. Groh, and T. Spies. 2007. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447: 482-486.
40. Taddeo, B., A. Esclatine, and B. Roizman. 2002. The patterns of accumulation of cellular RNAs in cells infected with a wild-type and a mutant herpes simplex virus 1 lacking the virion host shutoff gene. Proc. Natl. Acad. Sci. USA 99: 17031-17036.
41. Tsakadze, N. L., S. D. Sithu, U. Sen, W. R. English, G. Murphy, and S. E. D'Souza. 2006. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J. Biol. Chem. 281: 3157-3164.
42. Hertel, L., and E. S. Mocarski. 2004. Global analysis of host cell gene expression late during cytomegalovirus infection reveals extensive dysregulation of cell cycle gene expression and induction of Pseudomitosis independent of US28 function. J. Virol. 78: 11988-12011.
43. Straat, K., R. de Klark, S. Gredmark-Russ, P. Eriksson, and C. Söderberg-Nauclér. 2009. Infection with human cytomegalovirus alters the MMP-9/TIMP-1 balance in human macrophages. J. Virol. 83: 830-835.
44. Bachman, K. E., J. G. Herman, P. G. Corn, A. Merlo, J. F. Costello, W. K. Cavenee, S. B. Baylin, and J. R. Graff. 1999. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 59: 798-802.
45. Gabriely, G., T. Wurdinger, S. Kesari, C. C. Esau, J. Burchard, P. S. Linsley, and A. M. Krichevsky. 2008. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 28: 5369-5380.
46. Garofalo, M., G. Di Leva, G. Romano, G. Nuovo, S. S. Suh, A. Ngankeu, C. Taccioli, F. Pichiorri, H. Alder, P. Secchiero, et al. 2009. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16: 498-509.
47. Yang, X., W. W. Du, H. Li, F. Liu, A. Khorshidi, Z. J. Rutnam, and B. B. Yang. 2013. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res. 41: 9688-9704.
48. Wang, F. Z., F. Weber, C. Croce, C. G. Liu, X. Liao, and P. E. Pellett. 2008. Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication. J. Virol. 82: 9065-9074.
49. Stark, T. J., J. D. Arnold, D. H. Spector, and G. W. Yeo. 2012. High-resolution profiling and analysis of viral and host small RNAs during human cytomegalovirus infection. J. Virol. 86: 226-235.
50. Stern-Ginossar, N., N. Saleh, M. D. Goldberg, M. Prichard, D. G. Wolf, and O. Mandelboim. 2009. Analysis of human cytomegalovirus-encoded microRNA activity during infection. J. Virol. 83: 10684-10693.
51. Qi, M., Y. Qi, Y. Ma, R. He, Y. Ji, Z. Sun, and Q. Ruan. 2013. Over-expression of human cytomegalovirus miR-US25-2-3p downregulates eIF4A1 and inhibits HCMV replication. FEBS Lett. 587: 2266-2271.
52. Qi, J. H., Q. Ebrahem, N. Moore, G. Murphy, L. Claesson-Welsh, M. Bond, A. Baker, and B. Anand-Apte. 2003. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 9: 407-415.
53. Welte, S. A., C. Sinzger, S. Z. Lutz, H. Singh-Jasuja, K. L. Sampaio, U. Eknigk, H. G. Rammensee, and A. Steinle. 2003. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur. J. Immunol. 33: 194-203.
54. Montag, C., J. A. Wagner, I. Gruska, B. Vetter, L. Wiebusch, and C. Hagemeier. 2011. The latency-associated UL138 gene product of human cytomegalovirus sensitizes cells to tumor necrosis factor alpha (TNF-alpha) signaling by upregulating TNF-alpha receptor 1 cell surface expression. J. Virol. 85: 11409-11421.
55. Le, V. T., M. Trilling, and H. Hengel. 2011. The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb'-encoded modulation of TNF- A signaling. J. Virol. 85: 13260-13270.
56. Dengler, T. J., M. J. Raftery, M. Werle, R. Zimmermann, and G. Schönrich. 2000. Cytomegalovirus infection of vascular cells induces expression of proinflammatory adhesion molecules by paracrine action of secreted interleukin-1beta. Transplantation 69: 1160-1168.
57. Carney, W. P., V. Iacoviello, and M. S. Hirsch. 1983. Functional properties of T lymphocytes and their subsets in cytomegalovirus mononucleosis. J. Immunol. 130: 390-393.
58. Giebel, S., R. Maccario, D. Lilleri, M. Zecca, M. A. Avanzini, M. Marconi, A. Di Cesare Merlone, G. Campanini, D. Montagna, P. Travaglino, et al. 2005. The immunosuppressive effect of human cytomegalovirus infection in recipients of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 36: 503-509.
59. Hirsch, M. S., and D. Felsenstein. 1984. Cytomegalovirus-induced immunosuppression. Ann. N. Y. Acad. Sci. 437: 8-15.